Compare Lennar Corporation (LEN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Novo Nordisk A/S — how do they compare? Lennar Corporation trades at $76.69 (market cap $18.44B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 9× Lennar Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Novo Nordisk A/S for 116 Days on average.
| LEN | NVO | |
|---|---|---|
Market Cap | $18.44B | $165.31B |
Volume | 6,012,214 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $63.98 |
52-Week Low | $74.44 | $35.29 |
Typical Hold Time | 67 Days | 116 Days |
Enterprise Value | $22.86B | $179.56B |
Dividend Yield | 2.58% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LEN trades at $77.60, up 1.93% today, but faces a bearish technical outlook with recent earnings misses and declining profitability. Revenue fell to $34.19B in 2025 with net income margin dropping to 6.07%, while valuation ratios like P/E of 14.7 and P/B of 0.86 suggest potential undervaluation. Berkshire Hathaway's increased stake to 11.2% contrasts with analyst caution, as the stock hovers near support at $76 amid weak housing market sentiment.
The stock presents a value opportunity given low P/B and P/S ratios, but risks include persistent earnings underperformance, high mortgage rates pressuring housing demand, and allegations in a short report. Analyst consensus is mixed with a $77.38 price target, implying limited upside, while institutional buying by Berkshire signals long-term confidence amid near-term headwinds.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
